Clinical Significance of STC1 Gene Expression in Patients with Colorectal Cancer

SHUZO TAMURA 1 , TAKASHI OSHIMA 2 , KAZUE YOSHIHARA 2 , AMANE KANAZAWA 1 , TAKANOBU YAMADA 1 , DAISUKE INAGAKI 1 , TSUTOMU SATO 2 , NAOTO YAMAMOTO 1 , MANABU SHIOZAWA 1 , SOICHIRO MORINAGA 1 , MAKOTO AKAIKE 1 , CHIKARA KUNISAKI 2 , KATSUAKI TANAKA 2 , MUNETAKA MASUDA 3 and TOSHIO IMADA 4

¹Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa-ken, 241-0815, Japan; ²Gastroenterological Center, Yokohama City University Medical Center, Kanagawa-ken, 232-0024, Japan; ³Department of Surgery, ⁴Yokohama City University, Kanagawa-ken, 236-0004, Japan

Abstract. Background: Recent studies suggest that altered patterns of stanniocalcin 1 (STC1) gene expression have a role in human carcinogenesis. This study examined the relationship between the relative expression of the STC1 gene and clinicopathological factors in patients with colorectal cancer. Patients and Methods: Surgical specimens of cancer tissue and adjacent normal mucosa were obtained from 202 patients with colorectal carcinomas. The relative expression levels of STC1 mRNA in the cancer and the normal adjacent mucosa were measured by quantitative real-time, reversetranscriptase polymerase chain reaction. Results: The relative expression levels of the STC1 gene were higher in the cancer tissue than in the normal adjacent mucosa and high expression of STC1 correlated with poor postoperative survival. Conclusion: High expression of the STC1 gene might be a useful predictor of poor postoperative outcome in patients with colorectal cancer.

Stanniocalcin (STC) is a glycoprotein hormone that regulates calcium and phosphate levels produced in bony fish by the corpuscle of Stannius, which is located near the kidney (1, 2). A human ortholog of fish STC, STC1, has been identified by molecular biological techniques (3, 4). Human *STC1* complementary DNA (cDNA) encodes a 247 amino-acid protein. The gene resides on the short arm of chromosome 8 (8p11.2-p21) and contains four exons (5, 6). In contrast to fish STC, mammalian STC1 is expressed in various tissues,

Correspondence to: Takashi Oshima, Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho Minami-ku, Yokohama, Kanagawa, 232-0024, Japan. E-mail: ohshimatakashi@yahoo.co.jp

Key Words: Prognostic factor, stanniocalcin 1, PCR, colorectal cancer.

including the kidney, ovary, prostate, thyroid, colon, bone and spleen (3, 4, 6), and appears to be involved in not only calcium/phosphate regulation (7-9), but also in diverse biological processes. Modulation of STC1 expression has demonstrated in numerous pathological physiological, and processes including pregnancy (10), lactation (10), angiogenesis (11-14), organogenesis (15-18), cerebral ischemia (19), hypertonic stress (20), oxidative stress (21), and apoptosis (22, 23). STC1 was originally cloned as part of a search for cancer-related genes, and recent studies have indicated that altered STC1 expression patterns may have a role in carcinogenesis. Increased STC1 gene expression has been found in hepatocellular (24, 25), colorectal (12, 25, 26), and medullary thyroid carcinomas (27), increased STC1 protein expression has been found in ovarian caner (28), and aberrant STC1 gene expression has been found in breast carcinomas (29-32). The mechanisms involved remain poorly understood and it remains unclear whether the expression of SCT1 is associated with the malignant potential of cancer. In agreement with other studies, the present results showed that STC1 gene expression levels were higher in the cancer tissue than in the normal adjacent mucosa. A paralog of STC1 (STC2) was identified by searching expressed sequence tag databases for sequences related to STC1 (2). STC2 cDNA has 34% homology with both STC1 and eel STC (2). STC2 is less strongly related to fish STC than to STC1. Similar to STC1, STC2 is expressed in various tissues and is associated with several types of cancer, including breast cancer (29), renal cell carcinoma (33), and colorectal cancer (34), but these proteins are thought to have different biological roles (2).

In this study, the expression levels of the STC1 gene were measured in cancer tissue and adjacent normal mucosa obtained from patients with colorectal cancer. To evaluate the clinical significance of STC1, the correlation between the relative expression of this gene and clinicopathological

0250-7005/2011 \$2.00+.40

Table I. PCR primers and conditions.

Gene	Primer	Annealing temperature (°C)	Product size (bp)
STC1	5'-AGGATGATTGCTGAGGTG-3' 5'-CTGTTGGAGAAGTGATTGG-3'	60	119
β-Actin	5'-AGTTGCGTTACACCCTTTCTTGAC-3' 5'-GCTCGCTCCAACCGACTGC-3'	60	171

features was examined. Additinally, the influence of *STC1* gene expression on the outcomes of patients with colorectal cancer was assessed.

Patients and Methods

Patients and samples. Surgical specimens of cancer tissue and adjacent normal mucosa were obtained from 202 patients with colorectal cancer who underwent surgery at Kanagawa Cancer Center and at the Gastroenterological Center of Yokohama City University Medical Center between 2002 and 2006. Informed consent was obtained from each patient. The ethics committees of Kanagawa Cancer Center and Yokohama City University Medical Center approved the protocol before initiation of the study. All the tissue samples were embedded in Optimal Cutting Temperature (OCT) compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan) and were immediately stored at –80°C until use. No patient had any other malignancies. The specimens were stained with hematoxylin and eosin and examined histopathologically. Sections that consisted of >80% carcinoma cells were used to prepare the total RNA.

Quantitative real-time, reverse-transcriptase polymerase chain reaction (PCR). The total RNA isolated from the colorectal cancer and adjacent normal mucosa was prepared with the use of Trizol (Gibco Life Tech, Gaithersburg, MD, USA). cDNA was synthesized from 2 µg of total RNA using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). After synthesis, the cDNA was diluted 1:4 with water and stored at -20°C until use. Quantitative real-time PCR was performed with an iQ SYBR-Green Supermix (Bio-Rad Laboratories). The PCR was carried out in a total volume of 15 µl containing cDNA derived from 75 ng of RNA, 0.27 µM of each primer, 7.5 µl of iQ SYBR-Green Supermix containing dATP, dCTP, dGTP and dTTP at concentrations of 400 µM each and 50 units/ml of iTaq DNA polymerase. The PCR consisted of 10 min at 94°C, followed by 50 cycles of denaturation of the cDNA for 30 s at 94°C, annealing for 30 s at 60°C, and a primer extension for 1 min at 72°C followed by 72°C for 10 min. The PCR primer sequences of STC1 and β -actin, used as an internal control, are shown in Table I.

Statistical analysis. The gene expression levels in colorectal cancer were compared with those in normal adjacent mucosa with the use of the Wilcoxon test. The relationships between the gene expression levels and potential explanatory variables, including age, gender, tumor size, histological type, depth of invasion, lymph node metastasis, location, lymphatic invasion, venous invasion and liver metastasis, were evaluated with the chi-square test. The postoperative survival rate was analyzed with the Kaplan-Meier method, and differences in survival rates were assessed with the logrank test. A Cox proportional-hazards model was used for

multivariate analysis. All the statistical analyses were performed using Dr.SPSS II, version 11.0.1 J for Windows software (SPSS Inc., Chicago, IL, USA). Two-sided *p*-values were calculated, and differences were considered significant at *p*-values of <0.05.

Results

STC1 mRNA expression. STC1 mRNA expression levels were significantly higher in the cancer tissues than in the normal adjacent mucosa (p=0.004; Figure. 1).

Relationship of STC1 gene expression level to clinico-pathological features. The expression levels of the STC1 gene were categorized as low or high in relation to the median value. The STC1 gene expression level was not related to age, gender, tumor size, histological type, depth of invasion, lymph node metastasis, tumor location, lymphatic invasion, or venous invasion. However, the STC1 gene expression level correlated with liver metastasis (low expression: 24/101 [23.8%], high expression: 38/101 [37.6%], p=0.047; Table II).

STC1 expression and postoperative survival. Overall survival curves were plotted according to STC1 mRNA expression level by the Kaplan-Meier method. The median follow-up period was 1178 days. In the study group as a whole (202 patients), the overall survival rate was significantly lower in the patients with high STC1 mRNA expression than in those with low expression (p=0.016; Figure 2).

Univariate analysis with Cox proportional-hazards model identified seven prognostic factors: histological type, tumor size, depth of invasion, lymph node invasion, lymphatic invasion, liver metastasis and *STC1* expression. The other clinicopathological features, such as age, gender, location, and venous invasion, were not statistically significant prognosis factors (Table III). A multivariate analysis of the prognosis factors with a Cox proportional-hazards model confirmed that high *STC1* expression was a significant independent predictor of poor survival in colorectal cancer (Table IV).

Discussion

Wascher *et al.* (32) reported that in early-stage breast cancer, the detection of *STC1* mRNA in bone marrow and blood significantly correlated with multiple histopathological




Figure 1. Comparison of STC1 mRNA expression levels between colorectal cancer tissue (C) and adjacent normal mucosa (N). Box boundaries, the 25th and 75th percentiles of the observed values; capped bars, the 10th and 90th percentiles; solid line, median. p-Value was calculated by the Wilcoxon test. STC1 gene expression levels were higher in cancer tissue than in normal adjacent mucosa (p=0.004).




Figure 2. Postoperative survival of patients with colorectal cancer.

prognostic factors, including primary tumor size, number of positive lymph nodes, TMN stage, and overall American Joint Committee on Cancer (AJCC) stage. Gerritsen *et al.* (12) proposed that increased *STC1* expression was related to tumor vasculature in colon cancer. Ieta *et al.* (34) reported that high *STC2* expression positively correlated with lymph node metastasis, lymphatic invasion, tumor depth, tumor size and AJCC stage in colorectal cancer and was associated with significantly poorer overall survival than low *STC2*

Table II. Relationship of STC1 gene expression level to clinicopathological features.

	STC1 exp			
Variable	Low (n=101)	High (n=101)	<i>p</i> -Value	
Age (years)	66.3±11.1	65.1±10.5	0.432	
Gender				
Male	52	59	0.480	
Female	49	43		
Tumor size				
≤5 cm	69	62	0.377	
>5 cm	32	39		
Histological type				
Well+mod	91	83	0.153	
Poor+muc	10	18		
Depth of invasion				
T1, T2	25	25	1.000	
T3, T4	76	76		
Lymph node metastasis				
Absent	54	49	0.574	
Present	47	52		
Location				
Colon	59	51	0.323	
Rectum	42	50		
Lymphatic invasion				
Absent	69	63	0.460	
Present	32	38		
Venous invasion				
Absent	44	31	0.080	
Present	57	70		
Liver metastasis				
Absent	77	63	0.047	
Present	24	38		

n: Number of patients, well: well-differentiated, mod: moderately differentiated, poor: poorly differentiated, muc: mucinous.

expression. However, the clinical significance of STC1 gene expression in colorectal cancer remains unclear. To our knowledge, no previous study has examined the relationship between STC1 expression and patient outcome. In the present study, STC1 expression was associated with liver metastasis.and high STC1 expression correlated with poor postoperative survival. Fujiwara et al. (25) and Wascher et al. (32) have suggested that STC1 mRNA might be a useful molecular marker for the detection of tumor cells in blood. Tumor cells expressing high levels of STC1 probably exist in the circulation and metastasize via the bloodstream, which would be consistent with the finding that a high STC1 expression level was associated with liver metastasis. In conclusion, high STC1 gene expression might be a useful predictor of poor postoperative survival in patients with colorectal cancer.

Table III. Univariate analysis of clinicopathological factors for overall survival.

Variable	n	Hazard ratio	95% CI	<i>p</i> -Value
Age (years)				
≤65	91	1		
>65	111	1.389	0.765-2.525	0.281
Gender				
Male	110	1		
Female	92	0.815	0.451-1.475	0.500
Tumor size				
≤5 cm	131	1		
>5 cm	71	2.379	1.324-4.275	0.004
Histological type				
Well, mod	174	1		
Poor, muc	28	2.410	1.220-4.761	0.011
Depth of invasion				
T1, T2	50	1		
T3, T4	152	16.802	2.314-121.974	0.005
Location				
Colon	110	1		
Rectum	92	1.526	0.847-2.747	0.159
Lymph node metastasi	s			
Absent	103	1		
Present	99	6.015	2.797-12.993	< 0.001
Lymphatic invasion				
Absent	132	1		
Present	70	3.587	1.971-6.526	< 0.001
Venous invasion				
Absent	75	1		
Present	127	1.550	0.797-3.015	0.196
Liver metastasis				
Absent	140	1		
Present	62	10.259	5.173-20.347	< 0.001
STC1				
Low	101	1		
High	101	2.091	1.135-3.854	0.018

n: Number of patients, CI: confidence interval, well: well-differentiated, mod: moderately differentiated, poor: poorly differentiated, muc: mucinous.

References

- Ishibashi K and Imai M: Prospect of stanniocalcin endocrine/ paracrine system in mammals. Am J Physiol Renal Physiol 282: F367-F375, 2002.
- 2 Chang AC, Jellineck DA and Reddel RR: Mammalian stanniocalcins and cancer. Endocr Relat Cancer 10: 359-373, 2003.
- 3 Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR and Reddel RR: A novel human cDNA highly homologous to the fish hormone stanniocalcin (STC). Mol Cell Endocrinol 112: 241-247, 1995.
- 4 Olsen HS, Cepeda MA, Zhang QQ, Rosen CA and Vozzolo BL: Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA 93: 1792-1796, 1996.
- 5 Chang AC, Jeffrey KJ, Tokutake Y, Shimamoto A, Neumann AA, Dunham MA, Cha J, Sugawara M, Furuichi Y and Reddel RR:

Table IV. Multivariate analysis of clinicopathological factors for overall survival.

Variable	Hazard ratio	95% CI	<i>p</i> -Value
Tumor size (>5 cm/≤5 cm)	1.467	0.805-2.676	0.211
Histological type (well, mod/poor, muc)	1.247	0.592-2.625	0.561
Depth of invasion (T3, T4/T1, T2)	6.192	0.818-46.853	0.077
Lymph node metastasis (present/absent)	2.774	1.246-6.177	0.012
Lymphatic invasion (present/absent)	1.397	0.708-2.759	0.335
Liver metastasis (present/absent)	5.165	2.510-10.627	< 0.001
STC1 (high/low)	1.882	1.014-3.494	0.045

CI: Confidence interval, well: well-differentiated, mod: moderately differentiated, poor: poorly differentiated, muc: mucinous.

- Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47: 393-398, 1998.
- 6 Varghese R, Wong CK, Deol H, Wagner GF and DiMattia GE: Comparative analysis of mammalian stanniocalcin genes. Endocrinology 139: 4714-4725, 1998.
- 7 Madsen KL, Tavernini MM, Yachimec C, Mendrick DL, Alfonso PJ, Buergin M, Olsen HS, Antonaccio MJ, Thomson AB and Fedorak RN: Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine. Am J Physiol 274: G96-G102, 1998.
- 8 Wagner GF, Vozzolo BL, Jaworski E, Haddad M, Kline RL, Olsen HS, Rosen CA, Davidson MB and Renfro JL: Human stanniocalcin inhibits renal phosphate excretion in the rat. J Bone Miner Res *12*: 165-171, 1997.
- 9 Lu M, Wagner GF and Renfro JL: Stanniocalcin stimulates phosphate reabsorption by flounder renal proximal tubule in primary culture. Am J Physiol 267: R1356-R1362, 1994.
- 10 Deol HK, Varghese R, Wagner GF and Dimattia GE: Dynamic regulation of mouse ovarian stanniocalcin expression during gestation and lactation. Endocrinology *141*: 3412-3421, 2000.
- 11 Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F, Draksharapu A, Lewin DA and Gerritsen ME: Gene expression profiling in an *in vitro* model of angiogenesis. Am J Pathol *156*: 1887-1900, 2000.
- 12 Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, Toy K, Winer J, Draksharapu A, Peale F, Wu TD and Williams PM: *In silico* data filtering to identify new angiogenesis targets from a large *in vitro* gene profiling data set. Physiol Genomics *10*: 13-20, 2002.
- 13 Wary KK, Thakker GD, Humtsoe JO and Yang J: Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer 2: 25, 2003.
- 14 Zlot C, Ingle G, Hongo J, Yang S, Sheng Z, Schwall R, Paoni N, Wang F, Peale FV Jr. and Gerritsen ME: Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. J Biol Chem 278: 47654-47659, 2003.
- 15 Jiang WQ, Chang AC, Satoh M, Furuichi Y, Tam PP and Reddel RR: The distribution of stanniocalcin 1 protein in fetal mouse tissues suggests a role in bone and muscle development. J Endocrinol *165*: 457-466, 2000.

- 16 Stasko SE and Wagner GF: Possible roles for stanniocalcin during early skeletal patterning and joint formation in the mouse. J Endocrinol 171: 237-248, 2001.
- 17 Stasko SE and Wagner GF: Stanniocalcin gene expression during mouse urogenital development: a possible role in mesenchymal –epithelial signalling. Dev Dyn 220: 49-59, 2001.
- 18 Yoshiko Y, Aubin JE and Maeda N: Stanniocalcin 1 (STC1) protein and mRNA are developmentally regulated during embryonic mouse osteogenesis: the potential of stc1 as an autocrine/paracrine factor for osteoblast development and bone formation. J Histochem Cytochem 50: 483-492, 2002.
- 19 Zhang K, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS and Andersson LC: Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci USA 97: 3637-3642, 2000.
- 20 Sheikh-Hamad D, Rouse D and Yang Y: Regulation of stanniocalcin in MDCK cells by hypertonicity and extracellular calcium. Am J Physiol Renal Physiol 278: F417-F424, 2000.
- 21 Nguyen A, Chang AC and Reddel RR: Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogen 28: 1982-1992, 2009.
- 22 Wu S, Yoshilo Y and De Luca F: Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J Biol Chem 281: 5120-5127, 2006.
- 23 Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, Dimattia G, Sullivan DE and Prockop DJ: Multipotent stromal cells (MSCs) are activated to reduce apoptosis in part by up-regulation and secretion of stanniocalcin-1 (STC-1). Stem Cells 27: 670-681, 2009.
- 24 Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137, 2001.
- 25 Fujiwara Y, Sugita Y, Nakamori S, Miyamoto A, Shiozaki K, Nagano H, Sakon M and Monden M: Assessment of stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol 16: 799-804, 2000.
- 26 Macartney-Coxson DP, Hood KA, Shi HJ, Ward T, Wiles A, O'Connor R, Hall DA, Lea RA, Royds JA, Stubbs RS and Rooker S: Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 8: 187, 2008.

- 27 Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, Murakumo Y, Murakami H, Sugiura H, Iwata H, Ishiguro N and Takahashi M: Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161: 249-256, 2002.
- 28 Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102: 812-827, 2010.
- 29 Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE and Venter DJ: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62: 1289-1295, 2002.
- 30 McCudden CR ,Majewski A, Chakrabarti S and Wagner GF: Colocalization of stanniocalcin-1 ligand and receptor in human breast carcinomas. Mol Cell Endocrinol 213: 167-172, 2004.
- 31 Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA and King MC: BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 99: 7560-7565, 2002.
- 32 Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D and Hoon DS: Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 9: 1427-1435, 2003.
- 33 Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, Jung K and Kristiansen G: Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 55: 669-678, 2009.
- 34 Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H and Mori M: Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer 125: 926-931, 2009.

Received August 3, 2010 Revised December 2, 2010 Accepted December 3, 2010